SCHEMBL16936621

SCHEMBL16936621

COc1ccc(Cn2nnnc2-c2c(Br)cc(B(O)O)cc2S(N)(=O)=O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
PKM P14618 1/20 0.39
PTGS2 P35354 1/20 0.39
HTT P42858 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ERCC5 P28715 1/20 0.38
FEN1 P39748 1/20 0.38
RAB9A P51151 1/20 0.38
USP2 O75604 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALOX15 P16050 2/20 0.37
HSD17B3 P37058 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16936765 0.87 PTGS2 (0.42) ALDH1A1PKMPTGS2HTTNPSR1
SCHEMBL16936327 0.82 NPC1 (0.45) PTGS2RAB9AL3MBTL1
SCHEMBL16936260 0.82 PTGS2 (0.43) ALDH1A1PKMPTGS2HTTERCC5
SCHEMBL16936754 0.76 PTGS2 (0.43) ALDH1A1PKMPTGS2HTTERCC5
SCHEMBL16936505 0.75 PTGS2 (0.43) ALDH1A1PKMPTGS2HTTNPSR1
SCHEMBL16936686 0.75 PTGS2 (0.42) ALDH1A1PKMPTGS2HTTERCC5
SCHEMBL16947853 0.74 ERCC5 (0.42) PTGS2ERCC5FEN1
SCHEMBL18234232 0.74 PTGS2 (0.46) PTGS2ERCC5FEN1
SCHEMBL16947935 0.74 AKR1C3 (0.39) ALDH1A1PKMPTGS2HTTNPSR1
SCHEMBL16936349 0.73 PTGS2 (0.41) ALDH1A1PKMPTGS2HTTERCC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3096754-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME (US) 2018-08-29 EP disclosed
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
EP-3096754-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-11-30 EP disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 US disclosed
WO-2015112441-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MGAM, MGAM2, GAA ALDH1A1 329/4885PKM 2536/4885PTGS2 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.